Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial

BACKGROUND: Liraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCO...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensterle, Mojca, Kravos, Nika Aleksandra, Goričar, Katja, Janez, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286837/
https://www.ncbi.nlm.nih.gov/pubmed/28143456
http://dx.doi.org/10.1186/s12902-017-0155-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286837/
https://www.ncbi.nlm.nih.gov/pubmed/28143456
http://dx.doi.org/10.1186/s12902-017-0155-9

Ejemplares similares